Millennium Management’s Xenon Pharmaceuticals XENE Stock Holding History

Millennium Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-65,000	Closed	-$2.61M	–	6528
2025 Q3	$2.61M	Buy	+65,000	New	+$2.29M	﹤0.01%	3802
2023 Q4	–	Sell	-10,000	Closed	-$342K	–	6614
2023 Q3	$342K	Buy	+10,000	New	+$374K	﹤0.01%	4861
2021 Q4	–	Sell	-15,000	Closed	-$229K	–	7456
2021 Q3	$229K	Buy	+15,000	New	+$261K	﹤0.01%	6025

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management's XENE Position: Q1 2026 in Review

Millennium Management reduced its Xenon Pharmaceuticals (XENE) stake by 68% in Q1 2026, selling an estimated $20M and leaving 201,785 shares worth $11.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2027.

Millennium Management first reported a position in XENE in Q4 2016 and has held it in 30 quarters since. The position peaked at $55.6M in Q3 2025. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Millennium Management held 201,785 shares of Xenon Pharmaceuticals worth $11.7M as of Q1 2026.
Millennium Management sold 433,271 Xenon Pharmaceuticals shares in Q1 2026, an estimated $20M.
Xenon Pharmaceuticals made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2027 holding.
Millennium Management first reported a position in Xenon Pharmaceuticals in Q4 2016 and has held it in 30 quarters since.
Millennium Management's Xenon Pharmaceuticals position peaked at $55.6M in Q3 2025.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.